SCHEMBL4128916

SCHEMBL4128916

CCOC(=O)c1c(OCCO)nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 5/20 0.46
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 5/20 0.45
HPGD P15428 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
DGAT1 O75907 1/20 0.42
SOAT1 P35610 1/20 0.42
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GPR119 Q8TDV5 3/20 0.40
CYP19A1 P11511 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124701 0.93 TP53 (0.43) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL4109766 0.88 KDM4E (0.50) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL2085454 0.88 RXFP1 (0.38) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL4108763 0.87 SMN1; SMN2 (0.47) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL2086776 0.87 ALDH1A1 (0.49) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL4112658 0.86 ALDH1A1 (0.43) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL4112279 0.85 TP53 (0.47) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL2085947 0.85 SMN1; SMN2 (0.46) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL2083306 0.84 TP53 (0.44) LMNASMN1; SMN2RAB9ANPC1POLB
SCHEMBL4114405 0.84 TP53 (0.44) LMNASMN1; SMN2RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD LMNA 3919/4885SMN1; SMN2 3307/4885RAB9A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.